Sodium-Glucose Co-Transporter Protein 2 Inhibitors Induced Hypercalcemia: A Case Series and Literature Review

BACKGROUND: Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors are the newest class of oral antihyperglycemic agents. To our knowledge, hypercalcemia has not been labeled as a side effect of this class; nevertheless, 2 cases have been reported over the last few years. CASE REPORT: We present...

Descripción completa

Detalles Bibliográficos
Autores principales: El Masri, Dana, Jamil, Yasser, Eid Fares, Jocelyne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association of Clinical Endocrinology 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8784712/
https://www.ncbi.nlm.nih.gov/pubmed/35097199
http://dx.doi.org/10.1016/j.aace.2021.07.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8784712/
https://www.ncbi.nlm.nih.gov/pubmed/35097199
http://dx.doi.org/10.1016/j.aace.2021.07.002

Ejemplares similares